LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2025
0mins
Source: Globenewswire
New Drug Application Update: LENZ Therapeutics is on track for FDA approval of its presbyopia treatment, LNZ100, with a target action date set for August 8, 2025, and plans for immediate commercial launch in late 2025 upon approval.
Financial Overview: As of December 31, 2024, LENZ reported $209.1 million in cash and equivalents, with reduced R&D expenses due to the completion of a Phase 3 study, while SG&A expenses increased as the company prepares for commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
